TD Cowen maintains Boston Scientific stock rating after cyberattack
TD Cowen maintained a Buy rating and $56.00 price target on Boston Scientific (BSX) after a cyberattack disrupted operations. The stock is near its 52-week low, down 54% YTD. The firm lowered estimates for 2026 but kept a positive outlook for 2027. Boston Scientific has not quantified the financial impact but expects to miss Q3 and full-year 2026 guidance. Analysts note the company's recovery efforts and undervaluation.
How this was made
The 30-second read
Why it matters
Analyst maintains bullish view, but the incident remains a near-term headwind.
Market read
Rating reiteration offers limited new trading insight; price target unchanged.
What to watch
Potential regulatory scrutiny and longer-term cost of cybersecurity upgrades.
Background
Boston Scientific suffered a cyberattack on Aug 25 that disrupted operations and guidance.
Ticker impact
TD Cowen reiterated a Buy rating and $56 price target for Boston Scientific after its cyberattack, noting the incident's impact on guidance.
Potential modest upside if recovery proceeds, but limited immediate catalyst.
Rating is a reaction to an existing event; no new material data released.
Market effects
Medical device sector may see heightened risk awareness after cyber incidents.
U.S. healthcare stocks could face short-term pressure.
Limited to companies with similar supply-chain exposure.
Counterpoint
The rating may be overly optimistic if recovery stalls.
Key entities
- companyBoston Scientific
Medical device manufacturer affected by cyberattack.
- analystTD Cowen
Equity research firm reiterating Buy rating.
